Clinical Trial Update: An Open-Label Extension Study Assessing the Long-Term Efficacy and Safety of ALX-0061 in Subjects With Rheumatoid Arthritis [Phase 2]

View source ↗

Summary

Open-label extension study in rheumatoid arthritis assessing long-term efficacy and safety of ALX-0061 (Phase 2).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• ALX-0061 (ALX-0061)

Snippet

Sponsor: Ablynx, a Sanofi company | Conditions: Rheumatoid Arthritis | Phase 2 | Status: COMPLETED | Results posted: 2019-07-19